BRD3731 是一种选择性的GSK3β抑制剂，抑制 GSK3β 和 GSK3α 的IC50值分别为 15 nM 和 215 nM。BRD3731 有潜力用于创伤后应激障碍 (PTSD) 精神障碍、糖尿病和神经退行性障碍的研究。

BRD3731 is a selective GSK3β inhibitor, with IC 50 s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders [1].

BRD3731 is a GSK3β- selective inhibitor extracted from patent US20160375006A1, compound example 272 [1]. BRD3731 (1-10 μM; 24 hours) inhibits the phosphorylation of CRMP2 in SH-SY5Y cells [1]. BRD3731 (20 μM; 24 hours) decreases β-catenin S33/37/T41 phosphorylation and induces β-catenin S675 phosphorylation in HL-60 cells [2]. BRD3731 (10-20 μM; 7-10 days) impairs colony formation in TF-1 and increases colony forming ability in the MV4-11 cell line [2]

2056262-07-6

C24H31N3O

377.52

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years